Severe epilepsy in children with Dravet and Lennox-Gastaut syndrome can be safely treated with a medicinal cannabis oil that includes, at low dose, the intoxicating compound in marijuana known as THC, preliminary results of a Phase 1 clinical study suggest.
“What makes these results really exciting is it opens up as a treatment option for kids who have failed to respond to traditional medications,” said Richard Huntsman, MD, pediatric neurologist and lead author of the study, said in a news release.
Preliminary trial results were reported in the study “Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy: Preliminary Results of the CARE-E Study,” published in the journal Frontiers in Neurology.
Increasing evidence suggests that non-psychotropic cannabis-derived compounds, such as pharmaceutical grade cannabidiol (CBD), can help to manage seizures in children with treatment-resistant epilepsy. But little guidance exists for doctors on the proper